Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

MYOSLID : A Critical Modulator of Cancer Hallmarks

Medhi, Kanupriya ; Mukherjee, Sagarika ; Dagar, Aastha ; Tiwari, Ashutosh Kumar ; Daffara, Sia ; Bana, Sanjana ; Uttam, Vivek ; Ansari, Md Rizwan ; Yadav, Vikas LU orcid and Tuli, Hardeep Singh , et al. (2025) In Genes 16(3).
Abstract

Despite being the leading cause of death worldwide, cancer still lacks precise biomarkers for effective targeting, limiting efforts to reduce mortality rates. This review explores the role and clinical significance of a newly identified long non-coding RNA, MYOSLID, in cancer progression. MYOSLID has emerged as a critical modulator in cancer progression by influencing key hallmarks such as proliferation, immune evasion, metastasis, and metabolic reprogramming. It promotes tumor cell growth by stabilizing hypoxia-inducible factor 1 and acting as a competing endogenous RNA (ceRNA) to sequester tumor-suppressive microRNAs like miR-29c-3p, thereby enhancing oncogene expression. It facilitates immune evasion by upregulating PD-L1,... (More)

Despite being the leading cause of death worldwide, cancer still lacks precise biomarkers for effective targeting, limiting efforts to reduce mortality rates. This review explores the role and clinical significance of a newly identified long non-coding RNA, MYOSLID, in cancer progression. MYOSLID has emerged as a critical modulator in cancer progression by influencing key hallmarks such as proliferation, immune evasion, metastasis, and metabolic reprogramming. It promotes tumor cell growth by stabilizing hypoxia-inducible factor 1 and acting as a competing endogenous RNA (ceRNA) to sequester tumor-suppressive microRNAs like miR-29c-3p, thereby enhancing oncogene expression. It facilitates immune evasion by upregulating PD-L1, suppressing T cell activation, and modulating necroptosis pathways involving RIPK1 and RIPK3. Additionally, MYOSLID drives metastasis by regulating epithelial–mesenchymal transition markers such as LAMB3 and Slug while promoting RAB13-mediated cytoskeletal remodeling and enhancing cancer cell invasion. We have obtained the expression of MYOSLID from TCGA and the ENCORI database. The expression of colorectal adenocarcinoma (COAD) and head and neck squamous cell carcinoma (HNSCC) is associated with poor prognosis and lower survival rate. Given its significant potential as a diagnostic biomarker and therapeutic target, further research is required to elucidate its precise molecular mechanisms and therapeutic applications in cancer treatment.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; and (Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
activating invasion and metastasis, avoiding immune destruction and cell death resistance, cancer hallmarks, colorectal cancer, deregulating cellular metabolism, gastric cancer, head and neck squamous cell carcinoma, LncRNA, MYOSLID, oral cell squamous carcinoma, osteosarcoma, sustaining proliferative signaling
in
Genes
volume
16
issue
3
article number
341
publisher
MDPI AG
external identifiers
  • scopus:105001152840
  • pmid:40149492
ISSN
2073-4425
DOI
10.3390/genes16030341
language
English
LU publication?
yes
id
ca3c9027-1c59-490b-a221-3d89c1df34f7
date added to LUP
2025-08-26 13:39:30
date last changed
2025-08-27 03:00:03
@article{ca3c9027-1c59-490b-a221-3d89c1df34f7,
  abstract     = {{<p>Despite being the leading cause of death worldwide, cancer still lacks precise biomarkers for effective targeting, limiting efforts to reduce mortality rates. This review explores the role and clinical significance of a newly identified long non-coding RNA, MYOSLID, in cancer progression. MYOSLID has emerged as a critical modulator in cancer progression by influencing key hallmarks such as proliferation, immune evasion, metastasis, and metabolic reprogramming. It promotes tumor cell growth by stabilizing hypoxia-inducible factor 1 and acting as a competing endogenous RNA (ceRNA) to sequester tumor-suppressive microRNAs like miR-29c-3p, thereby enhancing oncogene expression. It facilitates immune evasion by upregulating PD-L1, suppressing T cell activation, and modulating necroptosis pathways involving RIPK1 and RIPK3. Additionally, MYOSLID drives metastasis by regulating epithelial–mesenchymal transition markers such as LAMB3 and Slug while promoting RAB13-mediated cytoskeletal remodeling and enhancing cancer cell invasion. We have obtained the expression of MYOSLID from TCGA and the ENCORI database. The expression of colorectal adenocarcinoma (COAD) and head and neck squamous cell carcinoma (HNSCC) is associated with poor prognosis and lower survival rate. Given its significant potential as a diagnostic biomarker and therapeutic target, further research is required to elucidate its precise molecular mechanisms and therapeutic applications in cancer treatment.</p>}},
  author       = {{Medhi, Kanupriya and Mukherjee, Sagarika and Dagar, Aastha and Tiwari, Ashutosh Kumar and Daffara, Sia and Bana, Sanjana and Uttam, Vivek and Ansari, Md Rizwan and Yadav, Vikas and Tuli, Hardeep Singh and Jain, Aklank}},
  issn         = {{2073-4425}},
  keywords     = {{activating invasion and metastasis; avoiding immune destruction and cell death resistance; cancer hallmarks; colorectal cancer; deregulating cellular metabolism; gastric cancer; head and neck squamous cell carcinoma; LncRNA; MYOSLID; oral cell squamous carcinoma; osteosarcoma; sustaining proliferative signaling}},
  language     = {{eng}},
  number       = {{3}},
  publisher    = {{MDPI AG}},
  series       = {{Genes}},
  title        = {{MYOSLID : A Critical Modulator of Cancer Hallmarks}},
  url          = {{http://dx.doi.org/10.3390/genes16030341}},
  doi          = {{10.3390/genes16030341}},
  volume       = {{16}},
  year         = {{2025}},
}